Leukodystrophies with late disease onset: An update

Current Opinion in Neurology

Volumn 23, Issue 3, 2010, Pages 234-241

  Köhler, Wolfgang ^a  

^a Fachkrankenhaus Hubertusburg   (Germany)

Author keywords

Enzyme replacement; Gene therapy; Hematopoietic stem cell transplantation; Inborn error of metabolism; Leukodystrophy

Indexed keywords

CEREBROSIDE SULFATASE; GALACTOSYLCERAMIDASE; LAMIN B; LAMIN B1; MEMBRANE PROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN; PROTEIN ABCD2; PROTEOLIPID PROTEIN; SULFATIDE; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ADRENOLEUKODYSTROPHY; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL; DEMYELINATION; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME REPLACEMENT; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; GLOBOID CELL LEUKODYSTROPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMAN; LEUKODYSTROPHY; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; METACHROMATIC LEUKODYSTROPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; ONSET AGE; PROTEIN FUNCTION; REVIEW; SAFETY; STEM CELL; WHITE MATTER;

ADRENOLEUKODYSTROPHY; AGE OF ONSET; ANIMALS; BRAIN DISEASES, METABOLIC, INBORN; CENTRAL NERVOUS SYSTEM; ENERGY METABOLISM; HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES; HUMANS; LEUKODYSTROPHY, GLOBOID CELL; LEUKODYSTROPHY, METACHROMATIC; LIPID METABOLISM DISORDERS; NERVE FIBERS, MYELINATED;

EID: 77951974494     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328338313a     Document Type: Review

References (90)

1. Kassmann CM, Lappe-Siefke C, Baes M, et al. Axonal loss and neuroin-flammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 2007; 39:969-976.
2. Kassmann CM, Nave KA. Oligodendroglial impact on axonal function and survival: a hypothesis. Curr Opin Neurol 2008; 21:235-241.
3. Nave KA,Trapp BD. Axon-glial signaling and theglial support of axon function. Annu Rev Neurosci 2008; 31:535-561.
4. BirchmeierC, Nave KA. Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia 2008; 56:1491-1497.
5. Sedel F,Tourbah A, Fontaine B, et al. Leukoencephalopathies associated with inborn errors of metabolism in adults. J Inherit Metab Dis 2008; 31:295-307.
6. Costello DJ, Eichler AF, Eichler FS. Leukodystrophies: classification, diagnosis, and treatment. Neurologist 2009; 15:319-328.
7. Kohlschütter A, Bley A, Brockmann K, et al. Leukodystrophies and other genetic metabolic leukoencephalopathies in children and adults. Brain Dev 2009; 32:82-89.
8. Köhler W. Diagnostic algorithm for the differentiation of leukodystrophies in early MS. J Neurol 2008; 255 (Suppl 6):123-126.
9. Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750-759.
10. Eichler F, Grodd W, Grant E, et al. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol 2009; 30:1893-1897.
11. Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleuko-dystrophy: implications for therapy. Mol Diagn Ther 2007; 11:381-384.
12. Hubbard WC, Moser AB, Liu AC, et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatogra-phy-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 2009; 97:212-220.
13. Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr Suppl 2008; 97:15-21.
14. Grossi S, Regis S, Rosano C, et al. Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles. Hum Mutat 2008; 29:E220-E230.
15. Deconinck N, Messaaoui A, Ziereisen F, et al. Metachromatic leukodystrophy without arylsulfatase A deficiency: a new case of saposin-B deficiency. Eur J Paediatr Neurol 2008; 12:46-50.
16. Kuchar L, Ledvinová J, Hreb́icekM, et al. Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations. Am J Med GenetA 2009; 149A:613-621.
17. Matzner U, Breiden B, Schwarzmann G, et al. Saposin B-dependent recon-stitution of arylsulfatase A activity in vitro and in cell culture models of metachromatic leukodystrophy. J Biol Chem 2009; 284:9372-9381.
18. Colsch B, Afonso C, Turpin JC, et al. Sulfogalactosylceramides in motor and psycho-cognitive adult metachromatic leukodystrophy: relations between clinical, biochemical analysis and molecular aspects. Biochim Biophys Acta 2008; 1780:434-440.
19. Tan MA, Fuller M, Zabidi-Hussin ZA, et al. Biochemical profiling to predict disease severity in metachromatic leukodystrophy. Mol Genet Metab 2010; 99:142-148.
20. Cesani M, Capotondo A, Plati T, et al. Characterization of new arylsulfatase A gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophy. Hum Mutat 2009; 30:E936-E945.
21. Biffi A, Lucchini G, Rovelli A, et al. Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant 2008; 42 (Suppl 2):S2-S6.
22. Meuleman N, Vanhaelen G, Tondreau T, et al. Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica 2008; 93:e11-e13.
23. Pierson TM, Bonnemann CG, Finkel RS, et al. Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy. Ann Neurol 2008; 64:583-587.
24. Lagranha VL, Baldo G, de Carvalho TG, et al. In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells. Metab Brain Dis 2008; 23:469-484.
25. Givogri MI, Bottai D, Zhu HL, et al. Multipotential neural precursors transplanted into the metachromatic leukodystrophy brain fail to generate oligodendrocytes but contribute to limit brain dysfunction. Dev Neurosci 2008; 30:340-357.
26. Colle MA, Piguet F, Bertrand L, et al. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in nonhuman primate. Hum Mol Genet 2010; 19:147-158.
27. Iwamoto N, Watanabe A, Yamamoto M, et al. Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J Gene Med 2009; 11:498-505.
28. Matzner U, Herbst E, Hedayati KK, et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 2005; 14:1139-1152.
29. Matzner U, Lüllmann-Rauch R, Stroobants S, et al. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol Ther 2009; 17:600-606.
30. Schroder S, Matthes F, Hyden P, et al. Site specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines. Glycobiology 2010; 20:248-259.
31. Sakai N. Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment. Brain Dev 2009; 31:485-487.
32. Giri S, Khan M, Nath N, et al. The role of AMPKin psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J Neu-rochem 2008; 105:1820-1833.
33. White AB, Givogri MI, Lopez-Rosas A, et al. Psychosine accumulates in membrane microdomains in the brain of Krabbe patients, disrupting the raft architecture. J Neurosci 2009; 29:6068-6077.
34. Romano A, De Simone R, Fasoli F, et al. Selective white matter involvement in a patient with late onset Krabbe disease: MR, MRspectroscopy, and diffusion tensor study. J Neuroimaging 2009; 19:191-193.
35. Provenzale JM, Peddi S, Kurtzberg J, et al. Correlation of neurodevelopmental features and MRI findings in infantile Krabbe's disease. AJR Am J Roentgenol 2009; 192:59-65.
36. Beslow LA, Schwartz ES, Bonnemann CG. Thickening and enhancement of multiple cranial nerves in conjunction with cystic white matter lesions in early infantile Krabbe disease. Pediatr Radiol 2008; 38:694-696.
37. Duffner PK, Caviness VS Jr, Erbe RW, et al. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the work shop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 2009; 11:450-454.
38. Duffner PK, Caggana M, Orsini JJ, et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009; 40:245-252; discussion 253-255.
39. Strazza M, Luddi A, Carbone M, et al. Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Mol Genet Metab 2009; 97:27-34.
40. Luzi P, Abraham RM, Rafi MA, et al. Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res 2009; 1300:146-158.
41. Raymond GV, Seidman R, Monteith TS, et al. Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci 2009; 290:70-74.
42. Semmler A, Bao X, Cao G, et al. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J Neurol 2009; 256:1277-1280.
43. Hein S, Schönfeld P, Kahlert S, Reiser G. Toxic effects of X-linked adrenoleu-kodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet 2008; 17:1 750-1761.
44. Uto T, Contreras MA, Gilg AG, Singh I. Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev Neurosci 2008; 30: 410-418.
45. Yanagisawa N, Shimada K, Miyazaki T, et al. Enhanced production of nitric oxide, reactive oxygen species, and pro-inflammatory cytokines in very long chain saturated fatty acid-accumulated macrophages. Lipids Health Dis 2008; 7:48.
46. Singh J, Khan M, Singh I. Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J Lipid Res 2009; 50:135-147.
47. Eichler FS, Ren JQ, Cossoy M, et al. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol 2008; 63:729-742.
48. Fourcade S, López-Erauskin J, Galino J, et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 2008; 17:1762-1773.
49. Deon M, Sitta A, Barschak AG, et al. Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy. J Neurol Sci 2008; 266:79-83.
50. Semmler A, Köhler W, Jung HH, et al. Therapy of X-linked adrenoleukodystrophy. Expert Rev Neurother 2008; 8:1367-1379.
51. Thoms S, Grønborg S, Gartner J.Organelle interplay in peroxisomal disorders. Trends Mol Med 2009; 15:293-302.
52. Camões F, Bonekamp NA, Delille HK, Schrader M. Organelle dynamics and dysfunction: a closer link between peroxisomes and mitochondria. J Inherit Metab Dis 2009; 32:163-180.
53. Singh I, Singh AK, Contreras MA. Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathol-ogy. J Child Neurol 2009; 24:1147-1157.
54. Brites P, Mooyer PA, El Mrabet L, et al. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain 2009; 132 (Pt 2):482-492.
55. Ratai E, Kok T, Wiggins C, et al. Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy. Arch Neurol 2008; 65:1488-1494.
56. Smith SA, Golay X, Fatemi A, et al. Quantitative magnetization transfer characteristics of the human cervical spinal cord in vivo: application to adrenomyeloneuropathy. Magn Reson Med 2009; 61:22-27.
57. Maier EM, Mayerhofer PU, Asheuer M, et al. X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. Biochem Biophys Res Commun 2008; 377:176-180.
58. Fourcade S, Ruiz M, Camps C, et al. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 2009; 296:E211-E221.
59. Weinhofer I, Kunze M, Rampler H, et al. Distinct modulatory roles for thyroid hormone receptors TRalpha and TRbeta in SREBP1-activated ABCD2 expression. Eur J Cell Biol 2008; 87:933-945.
60. Genin EC, Gondcaille C, Trompier D, Savary S. Induction of the adrenoleu-kodystrophy-related gene (ABCD2) by thyromimetics. J Steroid Biochem Mol Biol 2009; 116:37-43.
61. Mastroeni R, Bensadoun JC, Charvin D, et al. Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adreno leukodystrophy mouse model. Ann Neurol 2009; 66:117-122.
62. Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004; 104:881-888.
63. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326:818-823.
64. Maletkovic J, Schiffmann R, Gorospe JR, et al. Genetic and clinical heterogeneity in eIF2B-related disorder. J Child Neurol 2008; 23:205-215.
65. Horzinski L, Gonthier C, Rodriguez D, et al. Exon deletion in the noncatalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity. Ann Hum Genet 2008; 72 (Pt 3):410-415.
66. Mathis S, Scheper GC, Baumann N, et al. The ovarioleukodystrophy. Clin Neurol Neurosurg 2008; 110:1035-1037.
67. Damon-Perriere N, Menegon P, Olivier A, et al. Intra-familial phenotypic heterogeneity in adult onset vanishing white matter disease. Clin Neurol Neurosurg 2008; 110:1068-1071.
68. Vanderver A, Hathout Y, Maletkovic J, et al. Sensitivity and specificity of decreased CSFasialotransferrin foreIF2B-related disorder. Neurology 2008; 70:2226-2232.
69. Sundblom J, Melberg A, Kalimo H, et al. MR imaging characteristics and neuropathology of the spinal cord in adult-onset autosomal dominant leuko-dystrophy with autonomic symptoms. AJNR Am J Neuroradiol 2009; 30:328-335.
70. Meijer IA, Simoes-Lopes AA, Laurent S, et al. A novel duplication confirms the involvement of 5q23.2 in autosomal dominant leukodystrophy. Arch Neurol 2008; 65:1496-1501.
71. Brussino A, Vaula G, Cagnoli C, et al. A family with autosomal dominant leukodystrophy linked to 5q23.2-q23.3 without lamin B1 mutations. Eur J Neurol 2009 [Epub ahead of print].
72. Freeman SH, Hyman BT, Sims KB, et al. Adult onset leukodystrophy with neuroaxonal spheroids: clinical, neuroimaging and neuropathologic observations. Brain Pathol 2009; 19:39-47.
73. Wider C, Van Gerpen JA, DeArmond S, et al. Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD) A single entity? Neurology 2009; 72:1953-1959.
74. Schaefer RM, Tylki-Szymańska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 2009; 69:2179-2205.
75. Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis 2008; 3:21.
76. Labauge P, Renard D, Castelnovo G, et al. Beta-mannosidosis: a new cause of spinocerebellar ataxia. Clin Neurol Neurosurg 2009; 111:109-110.
77. Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 2008; 94:391-396.
78. Shapiro BE, Pastores GM, Gianutsos J, et al. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med 2009; 11:425-433.
79. Bach G. Mucolipidosis type IV. Mol Genet Metab 2001; 73:197-203.
80. Mochel F, Sedel F, Vanderver A, et al. Cerebellar ataxia with elevated cerebrospinal free sialic acid (CAFSA). Brain 2009; 132 (Pt 3):801-809.
81. Lossos A, Khoury M, Rizzo WB, et al. Phenotypic variability among adult siblings with Sjögren-Larsson syndrome. Arch Neurol 2006; 63:278-280.
82. Keren Z, Falik-ZaccaiTC. Cerebrotendinousxanthomatosis (CTX): a treatable lipid storage disease. Pediatr Endocrinol Rev 2009; 7:6-11.
83. Hörster F, Surtees R, Hoffmann GF. Disorders of intermediary metabolism: toxic leukoencephalopathies. J Inherit Metab Dis 2005; 28:345-356.
84. Padiath QS, Saigoh K, Schiffmann R, et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 2006; 38:1114-1123.
85. Scheper GC, van der Klok T, van Andel RJ, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007; 39:534-539.
86. Blattner R, Von Moers A, Leegwater PA, et al. Clinical and genetic heterogeneity in megalencephalic leukoencephalopathy with subcortical cysts (MLC). Neuropediatrics 2003; 34:215-218.
87. Roe CR, Bottiglieri T, Wallace M, et al. Adult polyglucosan body disease (APBD): anaplerotic diet therapy (triheptanoin) and demonstration of defective methylation pathways. Mol Genet Metab 2009 [Epub ahead of print].
88. Pantoni L, Pescini F, Nannucci S, et al. Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology 2010; 74:57-63.
89. van der Knaap MS, Ramesh V, Schiffmann R, et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 2006; 66:494-498.
90. Pareyson D, Fancellu R, Mariotti C, et al. Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain 2008; 131:2321-2331.